Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment - Ogasawara, Ken; Smith, William B.; Xu, Christine; Yin, Jian; Palmisano, Maria; Krishna, Gopal (Cancer chemotherapy and pharmacology, 2020)
Keywords: Adolescent; Adult; Aged; Area Under Curve; Cancer Research; Case-Control Studies; Dosage; End-stage renal disease; Enzyme inhibitors; Female; Follow-Up Studies; Humans; Janus kinase; Janus kinase 2; Janus Kinase 2 - antagonists & inhibitors; Kidney diseases; Kidney Failure, Chronic - drug therapy; Kidney Failure, Chronic - enzymology; Kidney Failure, Chronic - pathology; Liver diseases; Liver Diseases - drug therapy; Liver Diseases - enzymology; Liver Diseases - pathology; Male; Maximum Tolerated Dose; Medicine; Medicine & Public Health; Middle Aged; Myelofibrosis; Oncology; Original Article; Pharmacokinetics; Pharmacology/Toxicology; Prognosis; Pyrrolidines - administration & dosage; Pyrrolidines - pharmacokinetics; Studies; Sulfonamides - administration & dosage; Sulfonamides - pharmacokinetics; Survival Rate; Tissue Distribution; Young Adult; Tolerability; Hepatic impairment; Renal impairment; Fedratinib; Pharmacokinetics